Rational approaches to human cancer immunotherapy

Journal of Leukocyte Biology

Volumn 73, Issue 1, 2003, Pages 3-29

  Davis, Ian D ^a   Jefford, Michael ^a   Parente, Phillip ^a   Cebon, Jonathan ^a  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

Author keywords

Antigens; Dendritic cells; Peptides; Review; T cells; Vaccines

Indexed keywords

CYTOKINE; T LYMPHOCYTE ANTIGEN; TUMOR ANTIGEN;

ANTIGEN PRESENTATION; CANCER IMMUNOTHERAPY; CANCER RESEARCH; DENDRITIC CELL; GENE TRANSFER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR REGRESSION;

ANIMALS; ANTIGEN-PRESENTING CELLS; CANCER VACCINES; HISTORY, 20TH CENTURY; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; NEOPLASMS; RESEARCH;

EID: 0037244743     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1189/jlb.0502261     Document Type: Review

References (325)

1. Hall, S. S. (1997) A Commotion in the Blood, New York, NY, Henry Holt.
2. Rhoads, C. P. (1946) Nitrogen mustards in treatment of neoplastic disease. J. Am. Med. Assoc. 131, 656.
3. Goodman, L. S., Wintrobe, M. M., Dameshek, W., Goodman, J. J., Gilman, A., McLennan, M. T. (1946) Nitrogen mustard therapy: use of methylbis(B-chloroethyl)aminohydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. J. Am. Med. Assoc. 132, 126-132.
4. Coley, W. B. (1893) The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. Am. J. Med. Sci. 105, 487-511.
5. Starnes, C. O. (1992) Coley's toxins in perspective. Nature 357, 11-12.
6. Leech, P. N. (1934) Erysipelas and Prodigiosus toxins (Coley). J. Am. Med. Assoc. 103, 1067-1069.
7. Knuth, A., Wölfel, T., Klehmann, E., Boon, T., Meyer zum Buschenfelde, K. H. (1989) Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection. Proc. Natl. Acad. Sci. USA 86, 2804-2808.
8. Inaba, K., Metlay, J. P., Crowley, M. T., Witmer-Pack, M., Steinman, R. M. (1990) Dendritic cells as antigen presenting cells in vivo. Int. Rev. Immunol. 6, 197-206.
9. Morton, D., Eilber, F. R., Malmgren, R. A., Wood, W. C. (1970) Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery 68, 158-163.
10. Eilber, F. R., Townsend, C. M. J., Morton, D. L. (1976) Results of BCG adjuvant immunotherapy for melanoma of the head and neck. Am. J. Surg. 132, 476-479.
11. Kantoff, P. W., Zietman, A. L., Wishnow, K. (1997) Bladder cancer. In Cancer Medicine (J. F. Holland, E. Frei III, R. C. Bast Jr., D. W. Kufe, D. L. Morton, R. R. Weichselbaum, eds.), Baltimore, MD, Williams and Wilkins, 2105-2123.
12. Lamm, D. L., Blumenstein, B. A., Crawford, E. D., Montie, J. E., Scardino, P., Grossman, H. B., Stanisic, T. H., Smith, J. A. J., Sullivan, J., Sarosdy, M. F., et al. (1991) A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. N. Engl. J. Med. 325, 1205-1209.
13. Gomella, L. G., Mastrangelo, M. J., McCue, P. A., Maguire, H. J., Mulholland, S. G., Lattime, E. C. (2001) Phase I study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer. J. Urol. 166, 1291-1295.
14. Tsang, K. Y., Zaremba, S., Nieroda, C. A., Zhu, M. Z., Hamilton, J. M., Schlom, J. (1995) Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J. Natl. Cancer Inst. 87, 982-990.
15. Marshall, J. L., Hawkins, M. J., Tsang, K. Y., Richmond, E., Pedicano, J. E., Zhu, M. Z., Schlom, J. (1999) Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen. J. Clin. Oncol. 17, 332-337.
16. Rosenberg, S. A., Zhai, Y., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Seipp, C. A., Einhorn, J. H., Roberts, B., White, D. E. (1998) Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J. Natl. Cancer Inst. 90, 1894-1900.
17. Eder, J. P., Kantoff, P. W., Roper, K., Xu, G. X., Bubley, G. J., Boyden, J., Gritz, L., Mazzara, G., Oh, W. K., Arlen, P., Tsang, K. Y., Panicali, D., Schlom, J., Kufe, D. W. (2000) A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin. Cancer Res. 6, 1632-1638.
18. Marshall. J. L., Hoyer, R. J., Toomey, M. A., Faraguna, K., Chang, P., Richmond, E., Pedicano, J. E., Gehan, E., Peck, R. A., Arlen, P., Tsang, K. Y., Schlom, J. (2000) Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anticarcinoembryonic antigen immune responses. J. Clin. Oncol. 18, 3964-3973.
19. Schutz, A., Oertli, D., Marti, W. R., Noppen, C., Padovan, E., Spagnoli, G. C., Heberer, M., Zajac, P. (2001) Immunogenicity of nonreplicating recombinant vaccinia expressing HLA-A201 targeted or complete MART-1/Melan-A antigen. Cancer Gene Ther. 8, 655-661.
20. Tindle, R. W., Fernando, G. J., Sterling, J. C., Frazer, I. H. (1991) A "public" T-helper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B-cell epitopes from cervical cancer-associated human papillomavirus genotypes. Proc. Natl. Acad. Sci. USA 88, 5887-5891.
21. Goerner, M., Gooley, T., Flowers, M. E. D., Sullivan, K. M., Kiem, H-P., Sanders, J. E., Martin, P. J., Storb, R. (2002) Morbidity and mortality of chronic GVHD after hematopoietic stem cell transplantation from HLA-identical siblings for patients with aplastic or refractory anemias. Biol. Blood Marrow Transplant. 8, 47-56.
22. Butturini. A., Gale, R. P. (1987) The role of T-cells in preventing relapse in chronic myelogenous leukemia. Bone Marrow Transplant. 2, 351-354.
23. Marmont, A. M. (1993) The graft versus leukemia (GVL) effect after allogeneic bone marrow transplantation for chronic myelogenous leukemia (CML). Leuk. Lymphoma 11 (Suppl. 1), 221-226.
24. Giralt, S. A., Kolb, H. J. (1996) Donor lymphocyte infusions. Curr. Opin. Oncol. 8, 96-102.
25. Falkenburg, J. H., Faber, L. M., van den Elshout, M., van Luxemburg-Heijs, S. A., Hooftman-den Otter, A., Smit, W. M., Voogt, P. J., Willemze, R. (1993) Generation of donor-derived antileukemic cytotoxic T-lymphocyte responses for treatment of relapsed leukemia after allogeneic HLA-identical bone marrow transplantation. J. Immunother. 14, 305-309.
26. Slavin. S., Ackerstein, A., Morecki, S., Gelfand, Y., Cividalli, G. (2001) Immunotherapy of relapsed resistant chronic myelogenous leukemia post allogeneic bone marrow transplantation with alloantigen pulsed donor lymphocytes. Bone Marrow Transplant. 28, 795-798.
27. Bettex-Galland, M., Studer, U. E., Walz, A., Dewald, B., Baggiolini, M. (1991) Neutrophil-activating peptide-1/interleukin-8 detection in human urine during acute bladder inflammation caused by transurethral resection of superficial cancer and bacillus Calmette-Guerin administration. Eur. Urol. 19, 171-175.
28. Findlay, G. W. M., MacCallum, F. O. (1937) An interference phenomenon in relation to yellow fever and other viruses. J. Pathol. Bacteriol. 44, 405-424.
29. Isaacs, A., Lindenmann, J. (1957) Virus interference. I. The interferon. Proc. R. Soc. Lond. 147, 258-267.
30. Isaacs, A., Lindenmann, J., Valentine, R. C. (1957) Virus interference, II. Some properties of interferon. Proc. R. Soc. Lond. 147, 268-273.
31. Gresser, I., (1961) Production of interferon by suspensions of human leukocytes. Proc. Soc. Exp. Biol. Med. 108, 799-803.
32. Gresser, I., Bourali, C., Levy, J. P., Fontaine-Brouty-Boye, D., Thomas, M. T. (1969) Increased survival in mice inoculated with tumor cells and treated with interferon preparations. Proc. Natl. Acad. Sci. USA 63, 51-57.
33. Bennet Jr., I. L., Beeson, P. B. (1953) Studies on the pathogenesis of fever, II. Characterization of fever-producing substances from polymorphonuclear leukocytes and from the fluid of sterile exudates. J. Exp. Med. 98, 493-508.
34. Quesada, J. R., Reuben, J., Manning, J. T., Hersh, E. M., Gutterman, J. U. (1984) Alpha interferon for induction of remission in hairy-cell leukemia. N. Engl. J. Med. 310, 15-18.
35. Carswell, E. A., Old, L. J., Kassel, R. L., Green, S., Fiore, N., Williamson, B. (1975) An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA 72, 3666-3670.
36. Morgan, D. A., Ruscetti, F. W., Gallo, R. (1976) Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 193, 1007-1008.
37. Rosenberg, S. A., Lotze, M. T., Muul, L. M., Leitman, S., Chang, A. E., Ettinghausen, S. E., Matory, Y. L., Skibber, J. M., Shiloni, E., Vetto, J. T., et al. (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med. 313, 1485-1492.
38. Rosenberg, S. A., Lotze, M. T., Yang, J. C., Aebersold, P. M., Linehan, W. M., Seipp, C. A., White, D. E. (1989) Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann. Surg. 210, 474-484.
39. Parkinson, D. R., Abrams, J. S., Wiemik, P. H., Rayner, A. A., Margolin, K. A., Van Echo, D. A., Sznol, M., Dutcher, J. P., Aronson, F. R., Doroshow, J. H. (1990) Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study. J. Clin. Oncol. 8, 1650-1656.
40. Bukowski, R. M., Goodman, P., Crawford, E. D., Sergi, J. S., Redman, B. G., Whitehead, R. P. (1990) Phase II trial of high-dose intermittent interleukin-2 in metastatic renal cell carcinoma: a Southwest Oncology Group study. J. Natl. Cancer Inst. 82, 143-145.
41. Rosenberg, S. A., Yang, J. C., Topalian, S. L., Schwartzentruber, D. J., Weber, J. S., Parkinson, D. R., Seipp, C. A., Einhorn, J. H., White, D. E. (1994) Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. J. Am. Med. Assoc. 271, 907-913.
42. Atkins, M. B., Lotze, M., Wiernik, P., Fisher, R., Margolin, K., Weiss, G., Abrams, J., Sznol, M., Parkinson, D., Hawkins, M., Paradise, C., Rosenberg, S. A. (1997) High-dose IL-2 therapy alone results in long-term durable complete remissions in patients with metastatic melanoma. In Proceedings of the American Society of Clinical Oncology, Denver, CO.
43. Barth, A., Wanek, L. A., Morton, D. L. (1995) Prognostic factors in 1,521 melanoma patients with distant metastases. J. Am. Coll. Surg. 181, 193-201.
44. Glassman, A. B. (1989) Interleukin-2 and lymphokine activated killer cells: promises and cautions. Ann. Clin. Lab. Sci. 19, 51-55.
45. Gold, P. J., Thompson, J. A., Markowitz, D. R., Neumann, S., Fefer, A. (1997) Metastatic renal cell carcinoma: long-term survival after therapy with high-dose continuous-infusion interleukin-2. Cancer J. Sci. Am. 3 (Suppl. 1), S85-S91.
46. Butler, L. D., Mohler, K. M., Layman, N. K., Cain, R. L., Riedl, P. E., Puckett, L. D., Bendele, A. M. (1989) Interleukin-2 induced systemic toxicity: induction of mediators and immunopharmacologic intervention. Immunopharmacol. Immunotoxicol, 11, 445-487.
47. Kilbourn, R. G., Gross, S. S., Jubran, A., Adams, J., Griffith, O. W., Levi, R., Lodato, R. F. (1990) NG-methyl-L-arginine inhibits tumor necrosis factor-induced hypotension: implications for the involvement of nitric oxide. Proc. Natl. Acad. Sci. USA 87, 3629-3632.
48. Meropol, N. J., Porter, M., Blumenson, L. E., Lindemann, M. J., Perez, R. P., Vaickus, L., Loewen, G. M., Creaven, P. J., Wilkes, K. A., Giedlin, M. A., Caligiuri, M. A. (1996) Daily subcutaneous injection of low-dose interleukin 2 expands natural killer cells in vivo without significant toxicity. Clin. Cancer Res. 2, 669-677.
49. Meropol, N. J., Barresi, G. M., Fehniger, T. A., Hitt, J., Franklin, M., Caligiuri, M. A. (1998) Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing. Cancer Immunol. Immunother. 46, 318-326.
50. Bajorin, D. F., Chapman, P. B., Wong, G., Coit, D. G., Kunicka, J., Dimaggio, J., Cordon-Cardo, C., Urmacher, C., Dantes, L., Templeton, M. A., et al. (1990) Phase I evaluation of a combination of monoclonal antibody R24 and interleukin 2 in patients with metastatic melanoma. Cancer Res. 50, 7490-7495.
51. Ziegler, L. D., Palazzolo, P., Cunningham, J., Janus, M., Itoh, K., Hayakawa, K., Hellstrom, I., Hellstrom, K. E., Nicaise, C., Dennin, R. (1992) Phase I trial of murine monoclonal antibody L6 in combination with subcutaneous interleukin-2 in patients with advanced carcinoma of the breast, colorectum, and lung. J. Clin. Oncol. 10, 1470-1478.
52. Wiseman, G. A., Scott, A. M., Lee, F-T., Gansen, D. N., Hopkins, W., Steinmetz, S., Ingle, J. N., Croghan, G. A., Burch, P. A., Davis, I., et al. (2001) Chimeric G250 (cG250) monoclonal antibody phase I dose escalation trial in patients with advanced renal cell carcinoma (RCC). In Proceedings of the American Society of Clinical Oncology, San Francisco, CA.
53. Atkins, M. B., Robertson, M. J., Gordon, M., Lotze, M. T., DeCoste, M., DuBois, J. S., Ritz, J., Sandler, A. B., Edington, H. D., Garzone, P. D., Mier, J. W., Canning, C. M., Battiato, L., Tahara, H., Sherman, M. L. (1997) Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin. Cancer Res. 3, 409-417.
54. Robertson, M. J., Cameron, C., Atkins, M. B., Gordon, M. S., Lotze, M. T., Sherman, M. L., Ritz, J. (1999) Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer. Clin. Cancer Res. 5, 9-16.
55. Leonard, J. P., Sherman, M. L., Fisher, G. L., Buchanan, L. J., Larsen, G., Atkins, M. B., Sosman, J. A., Dutcher, J. P., Vogelzang, N. J., Ryan, J. L. (1997) Effects of single-dose interleukin-12 exposure on interleukin-12associated toxicity and interferon-gamma production. Blood 90, 2541-2548.
56. Noguchi, Y., Richards, E. C., Chen, Y. T., Old, L. J. (1995) Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. Proc. Natl. Acad. Sci. USA 92, 2219-2223.
57. Lotze, M. T., Hellerstedt, B., Stolinski, L., Tueting, T., Wilson, C., Kinzler, D., Vu, H., Rubin, J. T., Storkus, W., Tahara, H., Elder, E., Whiteside, T. (1997) The role of interleukin-2, interleukin-12, and dendritic cells in cancer therapy. Cancer J. Sci. Am. 3, S109-S114.
58. Parihar, R., Dierksheide, J., Hu, Y., Carson III, W. E. (2002) Interleukin-12 enhances the immune effects of an anti-Her2 monoclonal antibody by activating a potent cytokine secretion program within natural killer cells. In American Association for Cancer Research, San Francisco, CA.
59. Kojima, T., Yamazaki, K., Tani, K., Kinoshita, I., Nishimura, M., Akita, H. D. (2002) Combination therapy of tumor-derived gp96 and GM-CSF or IL-12-gene transduced tumor cells in the control of LLC tumor. In American Association for Cancer Research, San Francisco, CA.
60. Singh, M., O'Hagan, D. (1999) Advances in vaccine adjuvants. Nat. Biotechnol. 17, 1075-1081.
61. Barr, I. G., Mitchell, G. F. (1996) ISCOMs (immunostimulating complexes): the first decade. Immunol. Cell Biol. 74, 8-25.
62. Ennis, F. A., Cruz, J., Jameson, J., Klein, M., Burt, D., Thipphawong, J. (1999) Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS). Virology 259, 256-261.
63. Cormier, J. N., Salgaller, M. L., Prevette, T., Barracchini, K. C., Rivoltini, L., Restifo, N. P., Rosenberg, S. A., Marincola, F. M. (1997) Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J. Sci. Am. 3, 37-44.
64. Salgaller, M. L., Marincola, F. M., Cormier, J. N., Rosenberg, S. A. (1996) Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res. 56, 4749-4757.
65. Kawakami, Y., Robbins, P. F., Wang, R. F., Parkhurst, M., Kang, X., Rosenberg, S. A. (1998.) The use of melanosomal proteins in the immunotherapy of melanoma. J. Immunother. 21, 237-246.
66. Miconnet, I., Koenig, S., Speiser, D., Krieg, A., Guillaume, P., Cerottini, J-C., Romero, P. (2002) CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide. J. Immunol. 168, 1212-1218.
67. Wild, J., Grusby, M. J., Schirmbeck, R., Reimann, J. (1999) Priming MHC-1-restricted cytotoxic T lymphocyte responses to exogenous hepatitis B surface antigen is CD4+ T cell dependent. J. Immunol. 163, 1880-1887.
68. Lipford, G. B., Bauer, M., Blank, C., Reiter, R., Wagner, H., Heeg, K. (1997) CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. Eur. J. Immunol. 27, 2340-2344.
69. Hellstrand, K., Asea, A., Dahlgren, C., Hermodsson, S. (1994) Histaminergic regulation of NK cells. Role of monocyte-derived reactive oxygen metabolites. J. Immunol. 153, 4940-4947.
70. Qin, Z., Noffz, G., Mohaupt, M., Blankenstein, T. (1997) Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocytemacrophage colony-stimulating factor gene-modified tumor cells. J. Immunol. 159, 770-776.
71. Hahne, M., Rimoldi, D., Schroter, M., Romero, P., Schreier, M., French, L. E., Schneider, P., Bornand, T., Fontana, A., Lienard, D., Cerottini, J. C., Tschopp, J. (1996) Melanoma cell expression of Fas(Apo-1/CD95) ligand - implications for tumor immune escape. Science 274, 1363-1366.
72. Chang, H. L., Gillett, N., Figari, I., Lopez, A. R., Palladino, M. A., Derynck, R. (1993) Increased transforming growth factor β expression inhibits cell proliferation in vitro, yet increases tumorigenicity and tumor growth of Meth A sarcoma cells. Cancer Res. 53, 4391-4398.
73. Kirkwood, J. M., Strawderman, M. H., Ernstoff., M. S., Smith, T. J., Borden, E. C., Blum, R. H. (1996) Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J. Clin. Oncol. 14, 7-17.
74. Lens, M. B., Dawes, M. (2002) Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. J. Clin. Oncol. 20, 1818-1825.
75. Morton, D. L., Eilber, F. R., Holmes, E. C., Ramming, K. P. (1978) Preliminary results of a randomized trial of adjuvant immunotherapy in patients with malignant melanoma who have lymph node metastases. Aust. N. Z. Surg. 48, 49-52.
76. Hersey, P. (1992) Active immunotherapy with viral lysates of micrometastases following surgical removal of high risk melanoma. World J. Surg. 16, 251-260.
77. Hersey, P., Edwards, A., Coates, A., Shaw, H., McCarthy, W., Milton, G. (1987) Evidence that treatment with vaccinia melanoma cell lysates (VMCL) may improve survival of patients with stage II melanoma. Treatment of stage II melanoma with viral lysates. Cancer Immunol. Immanother. 25, 257-265.
78. Hersey, P. (1993) Evaluation of vaccinia viral lysates as therapeutic vaccines in the treatment of melanoma. Ann. N. Y. Acad. Sci. 690, 167-177.
79. Hersey, P., Edwards, A., D'Alessandro, G., MacDonald, M. (1986) Phase II study of vaccinia melanoma cell lysates (VMCL) as adjuvant to surgical treatment of stage II melanoma. II. Effects on cell mediated cytotoxicity and leucocyte dependent antibody activity: immunological effects of VMCL in melanoma patients. Cancer Immunol. Immunother. 22, 221-231.
80. Hersey, P., Coates, A. S., McCarthy, W. H., Thompson, J. F., Sillar, R. W., McLeod, R., Gill, P. G., Coventry, B. J., McMullen, A., Dillon, H., Simes, R. J. (2002) Adjuvant immunotherapy of patients with high-risk melanoma using vaccina viral lysates: results of a randomized trial. J. Clin. Oncol. 20, 4181-4190.
81. Restifo, N. P. (1996) The new vaccines: building viruses that elicit antitumor immunity. Curr. Opin. Immunol. 8, 658-663.
82. Rosenberg, S. A. (2000) The development of cancer vaccines. In Cancer Vaccines, New York, NY.
83. Marchand, M., Weynants, P., Rankin, E., Arienti, F., Belli, F., Parmiani, G., Cascinelli, N., Bourlond, A., Vanwijck, R., Humblet, Y., et al. (1995) Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3 (letter). Int. J. Cancer 63, 883-885.
84. Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., Sawyers, C. L. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031-1037.
85. Gross, L. (1943) Intradermal immunization of C3H mice against a sarcoma that originated in an animal of the same line. Cancer Res. 3, 326-333.
86. Gold, P., Freedman, S. O. (1965) Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J. Exp. Med. 121, 439-462.
87. Abelev, G. I. (1971) Alpha-fetoprotein in ontogenesis and its association with malignant tumors. Adv. Cancer Res. 14, 295-358.
88. Van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., Boon, T. (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254, 1643-1647.
89. Boon, T., van der Bruggen, P. (1996) Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183, 725-729.
90. Boon, T., Coulie, P. G., Van den Eynde, B. (1997) Tumor antigens recognized by T cells. Immunol. Today 18, 267-268.
91. Rosenberg, S. A. (1999) A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10, 281-287.
92. Rosenberg, S. A. (2001) Progress in human tumour immunology and immunotherapy. Nature 411, 380-384.
93. Cox, A. L., Skipper, J., Chen, Y., Henderson, R. A., Darrow, T. L., Shabanowitz, J., Engelhard, V. H., Hunt, D. F., Slingluff Jr., C. L. (1994) Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264, 716-719.
94. Hunt, D. F., Henderson, R. A., Shabanowitz, J., Sakaguchi, K., Michel, H., Sevilir, N., Cox, A. L., Appella, E., Engelhard, V. H. (1992) Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 255, 1261-1263.
95. Sahin, U., Tureci, O., Pfreundschuh, M. (1997) Serological identification of human tumor antigens. Curr. Opin. Immunol. 9, 709-716.
96. Chen, Y. T., Scanlan, M. J., Sahin, U., Türeci, O., Gure, A. O., Tsang, S., Williamson, B., Stockert, E., Pfreundschuh, M., Old, L. J. (1997) A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl. Acad. Sci. USA 94, 1914-1918.
97. Valmori, D., Dutoit, V., Lienard, D., Rimoldi, D., Pittet, M. J., Champagne, P., Ellefsen, K., Sahin, U., Speiser, D., Lejeune, F., Cerottini, J. C., Romero, P. (2000) Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res. 60, 4499-4506.
98. Jager, E., Jager, D., Karbach, J., Chen, Y. T., Ritter, G., Nagata, Y., Gnjatic, S., Stockert, E., Arand, M., Old, L. J., Knuth, A. (2000) Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma. J. Exp. Med. 191, 625-630.
99. Gilboa, E. (1999) The makings of a tumor rejection antigen. Immunity 11, 263-270.
100. Alexander-Miller, M. A., Leggatt, G. R., Sarin, A., Berzofsky, J. A. (1996) Role of antigen, CD8, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL. J. Exp. Med. 184, 485-492.
101. Anichini, A., Mortarini, R., Maccalli, C., Squarcina, P., Fleischhaner, K., Mascheroni, L., Parmiani, G. (1996) Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma. J. Immunol. 156, 208-217.
102. Parkhurst, M. R., Fitzgerald, E. B., Southwood, S., Sette, A., Rosenberg, S. A., Kawakami, Y. (1998) Identification of a shared HLA-A*0201restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). Cancer Res. 58, 4895-4901.
103. Kawashima, I., Hudson, S. J., Tsai, V., Southwood, S., Takesako, K., Appella, E., Sette, A., Celis, E. (1998) The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum. Immunol. 59, 1-14.
104. Schultze, J. L., Vonderheide, R. H. (2001) From cancer genomics to cancer immunotherapy: toward second-generation tumor antigens. Trends Immunol. 22, 516-523.
105. Vonderheide, R. H., Hahn, W. C., Schultze, J. L., Nadler, L. M. (1999) The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 10, 673-679.
106. Scanlan, M. J., Gordon, C. M., Wiiliamson, B., Lee, S. Y., Chen, Y. T., Stockert, E., Jungbluth, A., Ritter, G., Jager, D., Jager, E., Knuth, A., Old, L. J. (2002) Identification of cancer/testis genes by database mining and mRNA expression analysis. Int. J. Cancer 98, 485-492.
107. Valmori, D., Gileadi, U., Servis, C., Dunbar, P. R., Cerottini, J-C., Romero, P., Cerundolo, V., Lévy, F. (1999) Modulation of proteasomal activity required for the generation of a cytotoxic T lymphocyte-defined peptide derived from the tumor antigen MAGE-3. J. Exp. Med. 189, 895-905.
108. Ayyoub, M., Stevanovic, S., Sahin, U., Guillaume, P., Servis, C., Rimoldi, D., Valmori, D., Romero, P., Cerottini, J-C., Rammensee, H-G., Pfreundschuh, M., Speiser, D., Levy, F. (2002) Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma. J. Immunol. 168, 1717-1722.
109. Schultz, E. S., Chapiro, J., Lurquin, C., Claverol, S., Burlet-Schiltz, O., Warnier, G., Russo, V., Morel, S., Levy, F., Boon, T., Van den Eynde, B. J., van der Bruggen, P. (2002) The production of a new MAGE-3 peptide presented to cytolytic T lymphocytes by HLA-B40 requires the immunoproteasome. J. Exp. Med. 195, 391-399.
110. Mackensen, A., Herbst, B., Chen, J. L., Köhler, G., Noppen, C., Herr, W., Spagnoli, G. C., Cerundolo, V., Lindemann, A. (2000) Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Int. J. Cancer 86, 385-392.
111. Marchand, M., van Baren, N., Weynants, P., Brichard, V., Drano, B., Tessier, M. H., Rankin, E., Parmiani, G., Arienti, F., Humblet, Y., Bourlond, A., Vanwijck, R., Liénard, D., Beauduin, M., Dietrich, P. Y., Russo, V., Kerger, J., Masucci, G., Jäger, E., De Greve, J., Atzpodien, J., Brasseur, F., Coulie, P. G., van der Bruggen, P., Boon, T. (1999) Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLAA1. Int. J. Cancer 80, 219-230.
112. Weber, J. S., Hua, F. L., Spears, L., Martyl, V., Kuniyoshi, C., Celis, E. (1999) A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete Freund's adjuvant in patients with resected high-risk melanoma. J. Immunother. 22, 431-440.
113. Thurner, B., Haendle, I., Roder, C., Dieckmann, D., Keikavoussi, P., Jonuleit, H., Bender, A., Maczek, C., Schreiner, D., von den Driesch, P., Bröcker, E. B., Steinman, R. M., Enk. A., Kämpgen, E. Schuler, G. (1999) Vaccination with MAGE-3A1 peptide-pulsed mature, monocytederived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 190, 1669-1678.
114. Gajewski, T. F., Fallarino, F., Ashikari, A., Sherman, M. (2001) Immunization of HLA-A2+ melanoma patients with MAGE-3 or Melan A peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12. Clin. Cancer Res. 7, 895s-901s.
115. Reynolds, S. R., Oratz, R., Shapiro, R. L., Hao, P., Yun, Z., Fotino, M., Vukmanovic, S., Bystryn, J. C. (1997) Stimulation of CD8+ T cell responses to MAGE-3 and Melan A/MART-1 by immunization to a polyvalent melanoma vaccine. Int. J. Cancer 72, 972-976.
116. Sehuler-Thurner, B., Dieckmann, D., Keikavoussi, P., Bender, A., Maczek, C., Jonuleit, H., Röder, C., Haendle, I., Leisgang, W., Dunbar, R., Cerundolo, V., von Den Driesch, P., Knop, J., Brocker, E. B., Enk, A., Kämpgen, E., Schuler, G. (2000) MAGE-3 and influenza-matrix peptidespecific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells. J. Immunol. 165, 3492-3496.
117. Banchereau, J., Palucka, A. K., Dhodapkar, M., Burkeholder, S., Taquet, N., Rolland, A., Taquet, S., Coquery, S., Wittkowski, K. M., Bhardwaj, N., Pineiro, L., Steinman, R., Fay, J. (2001) Immune and clinical responses in patients with metastatic melaiiomamelanoma to CD34(+) progenitorderived dendritic cell vaccine. Cancer Res. 61, 6451-6458.
118. Sadanaga, N., Nagashima, H., Mashino, K., Tahara, K., Yamaguchi, H., Ohta, M., Fujie, T., Tanaka, F., Inoue, H., Takesako, K., Akiyoshi, T., Mori, M. (2001) Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin. Cancer Res. 7, 2277-2284.
119. Jager, E., Chen, Y. T., Drijfhout, J. W., Karbach, J., Ringhoffer, M., Jager, D., Arand, M., Wada, H., Noguchi, Y., Stockert, E., Old, L. J., Knuth, A. (1998) Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J. Exp. Med. 187, 265-270.
120. Wang, F., Bade, E., Kuniyoshi, C., Spears, L., Jeffery, G., Marty, V., Groshen, S., Weber, J. (1999) Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin. Cancer Res. 5, 2756-2765.
121. Panelli, M. C., Wunderlich, J., Jeffries, J., Wang, E., Mixon, A., Rosenberg, S. A., Marincola, F. M. (2000) Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. J. Immunother. 23, 487-498.
122. Valmori, D., Fonteneau, J-F., Lizana, C. M., Gervois, N., Liénard, D., Rimoldi, D., Jongeneel, V., Jotereau, F., Cerottini, J-C., Romero, P. (1998) Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J. Immunol. 160, 1750-1758.
123. Castelli, C., Storkus, W. J., Maeurer, M. J., Martin, D. M., Huang, E. C., Pramanik, B. N., Nagabhushan, T. L., Parmiani, G., Lotze, M. T. (1995) Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes. J. Exp. Med. 181, 363-368.
124. Pass, H. A., Schwarz, S. L., Wunderlich, J. R., Rosenberg, S. A. (1998) Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay. Cancer J. Sci. Am. 4, 316-323.
125. Slingluff Jr., C. L., Yamshchikov, G., Neese, P., Galavotti, H., Eastham, S., Engelhard, V. H., Kittlesen, D., Deacon, D., Hibbitts, S., Grosh, W. W., Petroni, G., Cohen, R., Wiernasz, C., Patterson, J. W., Conway, B. P., Ross, W. G. (2001) Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin. Cancer Res, 7, 3012-3024.
126. Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwarz, S. L., Spiess, P. J., Wunderlich, J. R., Parkhurst, M. R., Kawakami, Y., Seipp, C. A., Einhorn, J. H., White, D. E. (1998) Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4, 321-327.
127. Lam, R., Wang, F., Jeffery, G., Marty, V., Kuniyoshi, J., Bade, E., Ryback, M. E., Weber, J. (2001) Phase I trial of intravenous peptidepulsed dendritic cells in patients with metastatic melanoma. J. Immunother. 24, 66-78.
128. Lee, K. H., Wang, E., Nielsen, M. B., Wunderlich, J., Migueles, S., Connors, M., Steinberg, S. M., Rosenherg, S. A., Marineola, F. M. (1999) Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J. Immunol. 163, 6292-6300.
129. Lee, P., Wang, F., Kuniyoshi, J., Rubio, V., Stuges, T., Groshen, S., Gee, C., Lau, R., Jeffery, G., Margolin, K., Marty, V., Weber, J. (2001) Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J. Clin. Oncol. 19, 3836-3847.
130. Yamshchikov, G. V., Barnd, D. L., Eastham, S., Galavotti, H., Patterson, J. W., Deacon, D. H., Teates, D., Neese, P., Grosh, W. W., Petroni, G., Engelhard, V. H., Slingluff Jr., C. L. (2001) Evaluation of peptide vaccine immunogenieity in draining lymph nodes and peripheral blood of melanoma patients. Int. J. Cancer 92, 703-711.
131. Mitchell, M. S., Darrah, D., Yeung, D., Halpern, S., Wallace, A., Voland, J., Jones, V., Kan-Mitchell, J. (2002) Phase I trial of adoptive immnnotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope. J. Clin. Oncol. 20, 1075-1086.
132. Lewis, J. J., Janetzki, S., Schaed, S., Panageas, K. S., Wang, S., Williams, L., Meyers, M., Butterworth, L., Livingston, P. O., Chapman, P. B., Houghton, A. N. (2000) Evaluation of CD8(+) T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide. Int. J. Cancer 87, 391-398.
133. Janetzki, S., Song, P., Gupta, V., Lewis, J. J., Houghton, A. N. (2000) Insect cells as HLA-restricted antigen-presenting cells for the IFN-gamma Elispot assay. J. Immunol. Methods 234, 1-12.
134. Bettinotti, M. P., Norris, R. D., Hackett, J. A., Thompson, C. O., Simonis, T. B., Stroncek, D., Marincola, F. M. (2000) Frequency of human
135. Wang, R. F., Parkhurst, M. R., Kawakami, Y., Robbins, P. F., Rosenberg, S. A. (1996) Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. J. Exp. Med. 183, 1131-1140.
136. Tjoa, B. A., Simmons, S. J., Bowes, V. A., Ragde, H., Rogers, M., Elgamal, A., Kenny, G. M., Cobb, O. E., Ireton, R. C., Troychak, M. J., Salgaller, M. L., Boynton, C. L., Murphy, G. P. (1998) Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 36, 39-44.
137. Murphy, G. P., Tjoa, B. A., Simmons, S. J., Ragde, H., Rogers, M., Elgamal, A., Kenny, G. M., Troychak, M. J., Salgaller, M. L., Boynton, A. L. (1999) Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment. Prostate 39, 54-59.
138. Murphy, G. P., Tjoa, B. A., Simmons, S. J., Jarisch, J., Bowes, V. A., Ragde, H., Rogers, M., Elgamal, A., Kenny, G. M., Cobb, O. E., Ireton, R. C., Troychak, M. J., Salgaller, M. L., Boynbton, A. L. (1999) Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate 38, 73-78.
139. Morse, M. A., Deng, Y., Coleman, D., Hull, S., Kitrell-Fisher, E., Nair, S., Schlom, J., Ryback, M. E., Lyedy, H. K. (1999) A phase I study of active immunotherapy with carcinoembryonic, antigen peptide (CAP-I)pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin. Cancer Res. 5, 1331-1338.
140. Fong, L., Hou, Y., Rivas, A., Benike, C., Yuen, A., Fisher, G. A., Davis, M. M., Engleman, E. G. (2001) Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc. Natl. Acad. Sci, USA 98, 8809-8814.
141. Brossart, P., Wirths, S., Stuhler, G., Reichardt, V. L., Kanz, L., Brugger, W. (2000) Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 96, 3102-3108.
142. Disis, M. L., Grabstein, K. H., Sleath, P. R., Cheever, M. A. (1999) Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine, Clin. Cancer Res. 5, 1289-1297.
143. Disis, M. L., Gooley, T. A., Rinn, K., Davis, D., Piepkorn, M., Cheever, M. A., Knutson, K. L., Schiffman, K. (2002) Generation of T-cell immunity, to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J. Clin. Oncol. 20, 2624-2632.
144. Gilewski, T., Adluri, S., Ragupathi, G., Zhang, S., Yao, T. J., Panageas, K., Moynahan, M., Houghton, A., Norton, L., Livingston, P. O. (2000) Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Clin. Cancer Res. 6, 1693-1701.
145. Musselli, C., Ragupathi, G., Gilewski, T., Panageas, K. S., Spinat, Y., Livingston, P. O. (2002) Reevaluation of the cellular immune response in breast cancer patients vaccinated with MUC1. Int. J. Cancer 97, 660-667.
146. van Driel, W. J., Ressing, M. E., Kenter, G. G., Brandt, R. M., Krul, E. J., van Rossum, A. B., Schuuring, E., Offringa, R., Bauknecht, T., Tamm-Hermelink, A., van Dam, P. A., Fleuren, G. J., Kast, W. M., Melief C. J., Trimbos, J. B. (1999) Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur. J. Cancer 35, 946-952.
147. Muderspach, L., Wilczynski, S., Roman, L., Bade, L., Felix, J., Small, L. A., Kast, W. M., Fascio, G., Marty, V., Weber, J. (2000) A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin. Cancer Res. 6, 3406-3416.
148. Wang, R. F., Wang, X., Atwood, A. C., Topalian, S. L., Rosenberg, S. A. (1999) Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science 284, 1351-1354.
149. Jager, D., Jager, E., Knuth, A. (2001) Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer. J. Clin. Pathol. 54, 669-674.
150. Renkvist, N., Castelli, C., Robbins, P. F., Parmiani, G. (2001) A listing of human tumor antigens recognized by T cells. Cancer Immunol. Immunother. 50, 3-15.
151. Davis, 1. D., Lotze, M. T. (2000) Melanoma peptide clinical trials. In Peptide-Based Cancer Vaccines (W. M. Kast, ed.), Austin, TX, Eurekah. com, 215-236.
152. Davis, I. D. (2000) An overview of cancer immunotherapy. Immnnol. Cell Biol. 78, 179-195.
153. Jager, E., Jager, D., Knuth, A. (2002) Clinical cancer vaccine trials. Curr. Opin. Immunol. 14, 178-182.
154. Jäger, E., Gnjatic, S., Nagata, Y., Stockert, E., Jäger, D., Karbach, J., Neumann, A., Rieckenberg, J., Chen, Y-T., Ritter, G., Hoffman, E., Arand, M., Old, L. J., Knuth, A. (2000) Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptidevaccinated patients with NY-ESO-1 + cancers. Proc. Natl. Acad. Sci. USA 97, 12198-12203.
155. Jager, E., Ringhoffer, M., Dienes, H. P., Arand, M., Karbach, J., Jager, D., Ilsemann, C., Hagedorn, M., Oesch, F., Knuth, A. (1996) Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int. J. Cancer 67, 54-62.
156. Luft, T., Rizkalla, M., Tai, T. Y., Chen, Q., MacFarlan, R. I., Davis, I. D., Maraskovsky, E., Cebon, J. (2001) Exogenous peptides presented by transporter associated with antigen processing (TAP)-deficient and TAP-competent cells: intracellular loading and kinetics of presentation. J. Immunol. 167, 2529-2537.
157. Romero, P., Gervois, N., Schneider, J., Escobar, P., Valmori, D., Pannetier, C., Steinle, A., Wolfel, T., Lienard, D., Brichard, V., van Pel, A., Jotereau, F., Cerottini, J. C. (1997) Cytolytic T lymphocyte recognition of the immunodominant HLA-A *0201-restricted Melan-A/MART-1 antigenic peptide in melanoma. J. Immunol. 159, 2366-2374.
158. Valmori, D., Fonteneau, J-F., Valitutti, S., Gervois, N., Dunbar, R., Lidnard, D., Rimoldi, D., Cerundolo, V., Jotereau, F., Cerottini, J-C., Speiser, D. E., Romero, P. (1999) Optimal activation of tumor-reactive T cells by selected antigenic peptide analogues. Int. Immunol. 11, 1971-1979.
159. Romero, P., Dutoit, V., Rubio-Godoy, V., Lienard, D., Speiser, D., Guillaume, P., Servis, K., Rimoldi, D., Cerottini, J. C., Valmori, D. (2001) CD8+ T-cell response to NY-ESO-1: relative antigenicity and in vitro immunogenicity of natural and analogue sequences. Clin. Cancer Res. 7, 766s-772s.
160. Chen, J. L., Dunbar, P. R., Gileadi, U., Jager, E., Gnjatic, S., Nagata, Y., Stockert, E., Panicali, D. L., Chen, Y. T., Knuth, A., Old, L. J., Cerundolo, V. (2000) Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL. J. Immunol. 165, 948-955.
161. Toes, R. E., Offringa, R., Blom, R. J., Melief, C. J., Kast, W. M. (1996) Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc. Natl. Acad. Sci. USA 93, 7855-7860.
162. Appelbaum, F. R. (2001) Haematopoietic cell transplantation as immunotherapy. Nature 411, 385-389.
163. Fernandez, N. C., Lozier, A., Flament, C., Ricciardi-Castagnoli, P., Bellet, D., Suter, M., Perrieaudet, M., Tursz, T., Maraskovsky, E., Zitvogel, L. (1999) Dendritic cells directly trigger NK cell functions: crosstalk relevant in innate anti-tumor immune responses in vivo. Nat. Med. 5, 405-411.
164. Luft, T., Jefford, M., Luetjens, P., Hochrein, H., Masterman K-A., Maliszewski, C., Shortman, K., Cebon, J., Maraskovsky, E. (2002) IL-1β enhances CD40 ligand-mediated cytokine secretion by human dendritic cells (DC): a mechanism for T cell-independent DC activation. J. Immunol. 168, 713-722.
165. Banchereau, J., Steinman, R. M. (1998) Dendritic cells and the control of immunity. Nature 392, 245-252.
166. Jefford, M., Maraskovsky, E., Cebon, J., Davis, I. D. (2001) The use of dendritic cells in cancer therapy, Lancet Oncol. 2, 343-353.
167. Steinman, R. M., Dhodapkar, M. (2001) Active immunization against cancer with dendritic cells: the near future. Int. J. Cancer 94, 459-473.
168. Morse, M. A., Coleman, R. E., Akabani, G., Niehaus, N., Coleman, D., Lyerly, H. K. (1.999) Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res. 59, 56-58.
169. Rains, N., Cannan, R. J., Chen, W., Stubbs, R. S. (2001) Development of a dendritic cell (DC)-based vaccine for patients with advanced colorectal cancer. Hepatogastroenterology 48, 347-351.
170. Kikuchi, T., Akasaki, Y., Iric, M., Homma, S., Abe, T., Ohno, T. (2001) Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol. Immunother. 50, 337-344.
171. Yu, J. S., Wheeler, C. J., Zeltzer, P. M., Ying, H., Finger, D. N., Lee, P. K., Yong, W. H., Incardona, F., Thompson, R. C., Riedinger, M. S., Zhang, W., Prins, R. M., Black, K. L. (2001) Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res. 61, 842-847.
172. Fujii, S., Shimizu, K., Fujimoto, K., Kiyokawa, T., Tsukamoto, A., Sanada, I., Kawano, F. (2001) Treatment of post-transplanted, relapsed patients with hematological malignancies by infusion of HLA-matched, allogeneic-dendritic cells (DCs) pulsed with irradiated tumor cells and primed T cells. Leuk. Lymphoma 42, 357-369.
173. Hsu, F. J., Benike, C., Fagnoni, F., Liles, T. M., Czerwinski, D., Taidi, B., Engleman, E. G., Levy, R. (1996) Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2, 52-58.
174. Timmerman, J. M., Czerwinski, D. K., Davis, T. A., Hsu, F. J., Benike, C., Hao, Z. M., Taidi, B., Rajapaksa, R., Caspar, C. B., Okada, C. Y., van Beckhoven, A., Liles, T. M., Engleman, E. G., Levy, R. (2002) Idiotypepulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 99, 1517-1526.
175. Nestle, F. O., Alijagic, S., Gilllet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., Schadendorf, D. (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4, 328-332.
176. Thomas, R., Chambers, M., Boytar, R., Barker, K., Cavanagh, L. L., MacFadyen, S., Smithers, M., Jenkins, M., Andersen, J. (1999) Immature human monocyte-derived dendritic cells migrate rapidly to draining lymph nodes after intradermal injection for melanoma immunotherapy. Melanoma Res. 9, 474-481.
177. Mukherji, B., Chakraborty, N. G., Yamasaki, S., Okino, T., Yamase, H., Sporn, J. R., Kurtzman, S. K., Ergin, M. T., Ozols, J., Meehan, J., Mauri, F. (1995) Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc. Natl. Acad. Sci. USA 92, 8078-8082.
178. Hu, X., Chakraborty, N. G., Sporn, J. R., Kurtzman, S. H., Ergin, M. T., Mukherji, B. (1996) Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res. 56, 2479-2483.
179. Lim, S. H., Bailey-Wood, R. (1999) Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma. Int. J. Cancer 83, 215-222.
180. Liso, A., Stockerl-Goldstein, K. E., Auffermann-Gretzinger, S., Benike, C. J., Reichardt, V., van Beckhoven, A., Rajapaksa, R., Engleman, E. G., Blume, K. G., Levy, R. (2000) Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. Biol. Blood Marrow Transplant. 6, 621-627.
181. Reichardt, V. L., Okada, C. Y., Liso, A., Benike, C. J., Stockerl-Goldstein, K. E., Engleman, E. G., Blume, K. G., Levy, R. (1999) Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma-a feasibility study. Blood 93, 2411-2419.
182. Titzer, S., Christensen, O., Manzke, O., Tesch, H., Wolf, J., Emmerieh, B., Carsten, C., Diehl, V., Bohlen, H. (2000) Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects. Br. J. Haematol. 108, 805-816.
183. Geiger, J. D., Hutchinson, R. J., Hohenkirk, L. F., McKenna, E. A., Yanik, G. A., Levine, J. E., Chang, A. E., Braun, T. M., Mule, J. J. (2001) Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res. 61, 8513-8519.
184. Burch, P. A., Breen, J. K., Buckner, J. C., Gastineau, D. A., Kaur, J. A., Laus, R. L., Padley, D. J., Peshwa, M. V., Pitot, H. C., Richardson, R. L., Smits, B. J., Sopapan, P., Strang, G., Valone, F. H., Vuk-Pavlovic, S. (2000) Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin. Cancer Res. 6, 2175-2182.
185. Small, E. J., Fratesi, P., Reese, D. M., Strang, G., Laus, R., Peshwa, M. V., Valone, F. H. (2000) Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J. Clin. Oncol. 18, 3894-3903.
186. Fong, L., Brockstedt, D., Benike, C., Wu, L., Engleman, E. G. (2001) Dendritic cells injected via different routes induce immunity in cancer patients. J. Immunol. 166, 4254-4259.
187. Tjoa, B. A., Erickson, S. J., Bowes, V. A., Ragde, H., Kenny, G. M., Cobb, O. E., Ireton, R. C., Troychak, M. J., Boynton, A. L., Murphy, G. P. (1997) Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides. Prostate 32, 272-278.
188. Tjoa, B. A., Simmons, S. J., Elgamal, A., Rogers, M., Ragde, H., Kenny, G. M., Troychak, M. J., Boynton, A. L., Murphy, G. P. (1999) Follow-up evaluation of a phase II prostate cancer vaccine trial. Prostate 40, 125-129.
189. Murphy, G. P., Tjoa, B. A., Simmons, S. J., Rogers, M. K., Kenny, G. M., Jarisch, J. (2000) Higher-dose and less frequent dendritic cell infusions with PSMA peptides in hormone-refractory metastatic prostate cancer patients. Prostate 43, 59-62.
190. Höltl, L., Rieser, C., Papesh, C., Ramoner, R., Bartsch, G., Thurnher, M. (1998) CD83+ blood dendritic cells as a vaccine for immunotherapy of metastatic renal-cell cancer. Lancet 352, 1358.
191. Höltl, L., Rieser, C., Papesh, C., Ramoner, R., Herold, M., Klocker, H., Radmayr, C., Stenzl, A., Bartsch, G., Thurnher, M. (1999) Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J. Urol. 161, 777-782.
192. Kugler, A., Stuhler, G., Walden, P., Zöller, G., Zobywalski, A., Brossart, P., Trefzer, U., Ullrich, S., Muller, C. A., Becker, V., Gross, A. J., Hemmerlein, B., Kanz, L., Moller, G. A., Ringert, R. H. (2000) Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat. Med. 6, 332-336.
193. Triozzi, P. L., Khurrani, R., Aldrich, W. A., Walker, M. J., Kirn, J. A., Jaynes, S. (2000) Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancer. Cancer 89, 2646-2654.
194. Bernhard, H., Disis, M. L., Heimfeld, S., Hand, S., Gralow, J. R., Cheever, M. A. (1995) Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells of the bone marrow and peripheral blood. Cancer Res. 55, 1099-1104.
195. Caux, C., Vanbervliet, B., Massacrier, C., Dezutter-Dambuyant, C., de Saint-Vis, B., Jacquet, C., Yoneda, K., Imamura, S., Schmitt, D., Banchereau, J. (1996) CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNF alpha. J. Exp. Med. 184, 695-706.
196. Romani, N., Reider, D., Heuer, M., Ebner, S., Kämpgen, E., Eibl, B., Niederwieser, D., Schuler, G. (1996) Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J. Immunol. Methods 196, 137-151.
197. Sallusto, F., Lanzavecchia, A. (1994) Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/ macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J. Exp. Med. 179, 1109-1118.
198. Thomas, R., Davis, L. S., Lipsky, P. E. (1993) Isolation and characterization of human peripheral blood dendritic cells. J. Immunol. 150, 821-834.
199. Thomas, R., Lipsky, P. E. (1994) Human peripheral blood dendritic cell subsets. Isolation and characterization of precursor and mature antigenpresenting cells. J. Immunol. 153, 4016-4028.
200. O'Doherty, U., Steinman, R. M., Peng, M., Cameron, P. U., Gezelter, S., Kopeloff, I., Swiggard, W. J., Pope, M., Bhardwaj, N. (1993) Dendritic cells freshly isolated from human blood express CD4 and mature into typical immunostimulatory dendritic cells after culture in monocyteconditioned medium. J. Exp. Med. 178, 1067-1076.
201. O'Doherty, U., Peng, M., Gezelter, S., Swiggard, W. J., Betjes, M., Bhardwaj, N., Steinman, R. M. (1994) Human blood contains two subsets of dendritic cells, one immunologically mature and the other immature. Immunology 82, 487-493.
202. Pulendran, B., Banchereau, J., Burkeholder, S., Kraus, E., Guinet, E., Chalouni, C., Caron, D., Maliszewski, C., Davoust, J., Fay, J., Palucka, K. (2000) Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo. J. Immunol. 165, 566-572.
203. Arpinati, M., Green, C. L., Heimfeld, S., Heuser, J. E., Anasetti, C. (2000) Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood 95, 2484-2490.
204. Maraskovsky, E., Daro, E., Roux, E., Teepe, M., Maliszewski, C. R., Hoek, J., Caron. D., Lebsack, M. E., McKenna, H. J. (2000) In vivo generation of human dendritic cell subsets by Flt3 ligand. Blood 96, 878-884.
205. Mitchell, D. A., Nair, S. K. (2000) RNA-transfected dendritic cells in cancer immunotherapy. J. Clin. Invest. 106, 1065-1069.
206. Boczowski, D., Nair, S. K., Snyder, D., Gilboa, E. (1996) Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med. 184, 465-472.
207. Boczkowski, D., Nair. S. K., Nam, J. H., Lyerly, H. K., Gilboa, E. (2000) Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res. 60, 1028-1034.
208. Nair, S. K., Boczkowski, D., Morse, M., Cumming, R. I., Lyerly, H. K., Gilboa, E. (1998) Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat. Biotechnol. 16, 364-369.
209. Arthur, J. F., Butterfield, L. H., Roth, M. D., Bui, L. A., Kiertscher, S. M., Lau, R., Dubinett, S., Glaspy, J., McBride, W. H., Economou, J. S. (1997) A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther. 4, 17-25.
210. Albert, M. L., Pearce, S. F., Francisco, L. M., Sauter, B., Roy, P., Silverstein, R. L., Bhardwaj, N. (1.998) Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J. Exp. Med. 188, 1359-1368.
211. Albert, M. L., Sauter, B., Bhardwaj, N. (1998) Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392, 86-89.
212. Zitvogel, L., Regnault, A., Lozier, A., Wolfers, J., Flament, C., Tenza, D., Ricciardi-Castagnoli, P., Raposo, G., Amigorena, S. (1998) Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat. Med. 4, 594-600.
213. Thery, C., Boussac, M., Veron, P., Ricciardi-Castagnoli, P., Raposo, G., Garin, J., Amigorena, S. (2001) Proteomic analysis of cendritic cellderived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles. J. Immunol. 166, 7309-7318.
214. Nestle, F. O., Banchereau, J., Hart, D. (2001) Dendritic cells: on the move from bench to bedside. Nat. Med. 7, 761-765.
215. Dhodapkar, M. V., Steinman, R. M., Krasovsky, J., Munz, C., Bhardwaj, N. (2001) Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J. Exp. Med. 193, 233-238.
216. Hawiger, D., Inaba, K., Dorsett, Y., Guo, M., Mahnke, K., Rivera, M., Raretch, J. V., Steinman, R. M., Nussenzweig, M. C. (2001) Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 194, 769-779.
217. Janeway, C. A. J. (1989) Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb. Symp. Quant. Biol. 54, 1-13.
218. Matzinger, P. (1994) Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12, 991-1045.
219. Fuchs, E. J., Matzinger, P. (1996) Is cancer dangerous to the immune system? Semin. Immunol. 8, 271-280.
220. Smyth, M. J., Godfrey, D. I., Trapani, J. A. (2001) A fresh look at tumor immunosurveillance and immunotherapy. Nat. Immunol. 2, 293-299.
221. Brenner, M. K., Heslop, H. E., Rooney, C. M. (1998) Gene and cell transfer for specific immunotherapy. Vox Sang. 74, 87-90.
222. Shedlock, D. J., Weiner, D. B. (2000) DNA vaccination: antigen presentation and the induction of immunity. J. Leukoc. Biol. 68, 793-806.
223. Cohen, E. P. (2001) DNA-based vaccines for the treatment of cancer - an experimental model. Trends Mol. Med. 7, 175-179.
224. Zwiebel, J. A. (2001) Cancer gene and oncolytic virus therapy. Semin. Oncol. 28, 336-343.
225. Stevenson, F. K., Rosenberg, W. (2001) DNA vaccination: a potential weapon against infection and cancer. Vox Sang. 80, 12-18.
226. Sotomayor, M. G., Hu, H., Antonia, S., Sotomayor, E. M., Pardoll, D. M. (2002) Advances in gene therapy for malignant melanoma. Cancer Control 9, 39-48.
227. Nelson, W. G., Simons, J. W., Mikhak, B., Chang, J. F., DeMarzo, A. M., Carducci, M. A., Kirn, M., Weber, C. E., Baccala, A. A., Goeman, M. A., et al. (2000) Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies. Cancer Chemother. Pharmacol. 46 (Suppl.), S67-S72.
228. Kusumoto, M., Umeda, S., Ikubo, A., Aoki, Y., Tawfik, O., Oben, R., Williamson, S., Jewell, W., Suzuki, T. (2001) Phase I clinical trial of irradiated autologous melanoma cells adenovirally transduced with human GM-CSF gene. Cancer Immunol. Immunother. 50, 373-381.
229. Simons, J. W., Mikhak, B., Chang, J. F., DeMarzo, A. M., Carducci, M. A., Lim, M., Weber, C. E., Baccala, A. A., Goemann, M. A., Clift, S. M., Ando, D. G., Levitsky, H. I., Cohen, L. K., Sanda, M. G., Mulligan, R. C., Partin, A. W., Carter, H. B., Piantadosi, S., Marshall, F. F., Nelson, W. G. (1999) Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res. 59, 5160-5168.
230. Jaffee, E. M., Hruban, R. H., Biedrzycki, B., Laheru, D., Schepers, K., Sauter, P. R., Goemann, M., Coleman, J., Grochow, L., Donehower, R. C., Lillemoe, K. D., O'Reilly, S., Abrams, R. A., Pardoll, D. M., Cameron, J. L., Yeo, C. J. (2001) Novel allogeneic granulocyte-macrophage colonystimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J. Clin. Oncol. 19, 145-156.
231. Newton, D. A., Acierno, P. M., Metts, M. C., Baron, P. L., Brescia, F. J., Gattoni-Celli, S. (2001) Semiallogeneic cancer vaccines formulated with granulocyte-macrophage colony-stimulating factor for patients with metastatic gastrointestinal adenocarcinomas: a pilot phase I study. J. Immunother. 24, 19-26.
232. Suminami, Y., Elder, E. M., Lotze, M. T., Whiteside, T. L. (1995) In situ interleukin-4 gene expression in cancer patients treated with genetically modified tumor vaccine. J. Immunother. 17, 238-248.
233. Ramsay, A. J., Kent, S. J., Strugnell, R. A., Suhrbier, A., Thomson, S. A., Ramshaw, I. A. (1999) Genetic vaccination strategies for enhanced cellular, humoral and mucosal immunity. Immunol. Rev. 171, 27-44.
234. Heiser, A., Dahm, P., Yancey, D. R., Maurice, M. A., Boczkowski, D., Nair, S. K., Gilboa. E., Vieweg, J. (2000) Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostatespecific CTL responses in vitro. J. Immunol. 164, 5508-5514.
235. Heiser, A., Maurice, M. A., Yancey, D. R., Wu, N. Z., Dahm, P., Pruitt, S. K., Boczkowski, D., Nair, S. K., Ballo, M. S., Gilboa, E., Vieweg, J. (2001) Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA. J. Immunol. 166, 2953-2960.
236. de Zoeten, E. F., Li, D., Cohen, E. P. (2001) Tumor immunity in mice immunized with fibroblasts transfected with tumor DNA. Adv. Exp. Med. Biol. 495, 393-401.
237. Scott, A. M., Welt, S. (1997) Antibody-based immunological therapies. Curr. Opin. Immunol. 9, 717-722.
238. Multani, P. S., Grossbard, M. L. (1998) Monoclonal antibody-based therapies for hematologic malignancies. J. Clin. Oncol. 16, 3691-3710.
239. Murray, J. L. (2000) Monoclonal antibody treatment of solid tumors: a coming of age. Semin. Oncol. 27, 64-70.
240. Scott, A. M., Cebon, J. (1997) Clinical promise of tumour immunology. Lancet 349 (Suppl. 2), 19-22.
241. Renner, C., Hartmann, F., Pfreundschuh, M. (2001) The future of monoclonal antibody engineering. Ann. Hematol. 80 (Suppl. 3), B127-B129.
242. Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, N. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707-712.
243. Pupa, S. M., Menard, S., Andreola, S., Colnaghi, M. I. (1993) Antibody response against the c-erbB-2 oneoprotein in breast carcinoma patients. Cancer Res. 53, 5864-5866.
244. Disis, M. L., Calenoff, E., McLaughlin, G., Murphy, A. E., Chen, W., Groner, B., Jeschke, M., Lydon, N., McGlynn, E., Livingston, R. B., et al. (1994) Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res. 54, 16-20.
245. Peoples, G. E., Goedegebuure, P. S., Smith, R., Linehan, D. C., Yoshino, I., Eberlein, T. J. (1995) Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc. Natl. Acad. Sci. USA 92, 432-436.
246. Fisk, B., Blevins, T. L., Wharton, J. T., Ioannides, C. G. (1995) Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J. Exp. Med. 181, 2109-2117.
247. Brossart, P., Stuhler, G., Flad, T., Stevanovic, S., Rammensee, H. G., Kanz, L., Brugger, W. (1998) Her-2/neu-derived peptides are tumorassociated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res. 58, 732-736.
248. Disis, M. L., Schiffman, K., Gooley, T. A., McNeel, D. G., Rinn, K., Knutson, K. L. (2000) Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization. Clin. Cancer Res. 6, 1347-1350.
249. Katsumata, M., Okudaira, T., Samanta, A., Clark, D. P., Drebin, J. A., Jolicoeur, P., Greene, M. I. (1995) Prevention of breast tumour development in vivo by downregulation of the p185neu receptor. Nat. Med. 1, 644-648.
250. Shak, S. (1999) Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. Semin. Oncol. 26, 71-77.
251. Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., Baselga, J., Norton, L. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792.
252. Stashenko, P., Nadler, L. M., Hardy, R., Schlossman, S. F. (1980) Characterization of a human B lymphocyte-specific antigen. J. Immunol. 125, 1678-1685.
253. Anderson, K. C., Bates, M. P., Slaughenhoupt, B. L., Pinkus, G. S., Schlossman, S. F., Nadler, L. M. (1984) Expression of human B cellassociated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 63, 1424-1433.
254. Press, O. W., Appelbaum, F., Ledbetter, J. A., Martin, P. J., Zarlin, J., Kidd, P., Thomas, E. D. (1987) Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 69, 584-591.
255. Liu, A. Y., Robinson, R. R., Murray Jr., E. D., Ledbetter, J. A., Hellstrom, I., Hellstrom, K. E. (1987) Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity. J. Immunol. 139, 3521-3526.
256. Reff, M. E., Carner, K., Chambers, K. S., Chinn, P. C., Leonard. J. E., Raab, R., Newman, R. A., Hanna, N., Anderson, D. R. (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83, 435-445.
257. McLaughlin, P., Grillo-Lopez, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence-Bruckler, I., White, C. A., Cabanillas, F., Jain, V., Ho, A. D., Lister, J., Wey, K., Shen, D., Dallaire, B. K. (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16, 2825-2833.
258. Witzig, T. E., Gordon, L. I., Cabanillas, F., Czuczman, M. S., Emmanouilides, C., Joyce, R., Pohlman, B. L., Bartlett, N. L., Wiseman, G. A., Padre, N., Grillo-Lopez, A. J., Multani, P., White, C. A. (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus fituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 20, 2453-2463.
259. Bross, P. F., Beitz, J., Chen, G., Chen, X. H., Duffy, E., Kieffer, L., Roy, S., Sridhara, R., Rahman, A., Williams, G., Pazdur, R. (2001) Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin. Cancer Res. 7, 1490-1496.
260. Dumont, F. J. (2001) Alemtuzumab (Millennium/ILEX). Curr. Opin. Investig. Drugs 2, 139-160.
261. Toes, R. E., Ossendorp, F., Offringa, R., Melief, C. J. (1999) CD4 T cells and their role in antitumor immune responses. J. Exp. Med. 189, 753-756.
262. Bennett, S. R., Carbone, F. R., Karamalis, F., Flavell, R. A., Miller, J. F., Heath, W. R. (1998) Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393, 478-480.
263. Schoenberger, S. P., Toes, R. E. M., van der Voort, E. I. H., Offringa, R., Melief, C. J. M. (1998) T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393, 480-483.
264. Ridge, J. P., Rosa, F. D., Matzinger, P. (1998) A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393, 474-478.
265. Greenberg, P. D. (1991) Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol. 49, 281-355.
266. Hung, K., Hayashi, R., Lafond-Walker, A., Lowenstein, C., Pardoll, D., Levitsky, H. (1998) The central role of CD4(+) T cells in the antitumor immune response. J. Exp. Med. 188, 2357-2368.
267. Nishikawa, H., Tanida, K., Ikeda, H., Sakakura, M., Miyahara, Y., Aota, T., Mukai, K., Watanabe, M., Kurihayashi, K., Old, L. J., Shiku, H. (2001) Role of SEREX-defined immunogenic wild-type cellular molecules in the development of tumor-specific immunity. Proc. Natl. Acad. Sci. USA 98, 14571-14576.
268. Georgopoulos, C., Welch, W. J. (1993) Role of the major heat shock proteins as molecular chaperones. Annu. Rev. Cell Biol. 9, 601-634.
269. Vanbuskirk, A., Crump, B. L., Margoliash, E., Pierce, S. K. (1989) A peptide binding protein having a role in antigen presentation is a member of the HSP70 heat shock family. J. Exp. Med. 170, 1799-1809.
270. Srivastava, P. K., Udono, H., Blachere, N. E., Li, Z. (1994) Heat shock proteins transfer peptides during antigen processing and CTL priming. Immunogenetics 39, 93-98.
271. Janetzki, S., Palla, D., Rosenhauer, V., Lochs, H., Lewis, J. J., Srivastava, P. K. (2000) Immunization of cancer patients with autologous cancerderived heat shock protein gp96 preparations: a pilot study. Int. J. Cancer 88, 232-238.
272. Caudill, M. M., Li, Z. (2001) HSPPC-96: a personalised cancer vaccine. Expert Opin. Biol. Ther. 1, 539-547.
273. Anonymous (2002) Cancer vaccine-antigenics. BioDrugs 16, 72-74.
274. Ganly, I., Kirn, D., Eckhardt, G., Rodriguez, G. I., Soutar, D. S., Otto, R., Robertson, A. G., Park, O., Culley, M. L., Heise, C., van Hoff, D. D., Kaye, S. B., Eckhardt, S. G. (2000) A phase I study, of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin. Cancer Res. 6, 798-806.
275. Khuri, F. R., Nemunaitis, J., Ganly, I., Arseneau, J., Tannock, I. F., Romel, L., Gore, M., Ironside, J., MacDougall, R. H., Heise, C., Randlev, B., Gillenwater, A. M., Bruso, P., Kaye, S. B., Hong, W. K., Kirn, D. H. (2000) A controlled trial of intratumoral ONYX-015, a selectivelyreplicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med. 6, 879-885.
276. Lamont, J. P., Nemunaitis, J., Kuhn, J. A., Landers, S. A., McCarly, T. M. (2000) A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience). Ann. Surg. Oncol. 7, 588-592.
277. Nemunaitis, J., Ganly, I., Khufi, F., Arseneau, J., Kuhn, J., McCarty, T., Landers, S., Maples, P., Romel, L., Randlev, B., Reid, T., Kaye, S., Kirn, D. (2000) Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res. 60, 6359-6366.
278. Nemunaitis, J., Khuri, F., Ganly, I., Arseneau, J., Posner, M., Vokes, E., Kuhn, J., McCarty, T., Landers, S., Blackburn, A., Romel, L., Randlev, B., Kaye, S., Kirn, D. (2001) Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J. Clin. Oncol. 19, 289-298.
279. Bergsland, E. K., Venook, A. P. (2002) Shedding old paradigms: developing viruses to treat cancer. J. Clin. Oncol. 20, 2220-2222.
280. Pecora, A. L., Rizvi, N., Cohen, G. I., Meropol, N. J., Sterman, D., Marshall, J. L., Goldberg, S., Gross, P., O'Neil, J. D., Groene, W. S., Roberts, M. S., Rabin, H., Bamat, M. K., Lorence, R. M. (2002) Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J. Clin. Oncol. 20, 2251-2266.
281. Krieg, A. M., Davis, H. L. (2001) Enhancing vaccines with immune stimulatory CpG DNA. Curr. Opin. Mol. Ther. 3, 15-24.
282. Brazolot Millan, C. L., Weeratna, R., Krieg, A. M., Siegrist, C. A., Davis, H. L. (1998) CpG DNA can induce strong Th1 humoral and cellmediated immune responses against hepatitis B surface antigen in young mice. Proc. Natl. Acad. Sci. USA 95, 15553-15558.
283. Jäger, E., Ringhoffer, M., Karbach, J., Arand, M., Oesch, F., Knuth, A. (1996) Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. Int. J. Cancer 66, 470-476.
284. Jäger, E., Stockert, E., Zidianakis, Z., Chen, Y. T., Karbach, J., Jäger, D., Arand, M., Ritter, G., Old, L. J., Knuth, A. (1999) Humoral immune responses of cancer patients against "cancer-testis" antigen NY-ESO-1: correlation with clinical events. Int. J. Cancer 84, 506-510.
285. Zinkernagel, R. M., Bachmann, M. F., Kundig, T. M., Oehen, S., Pirchet, H., Hengartner, H. (1996) On immunological memory. Annu. Rev. Immunol. 14, 333-367.
286. Kundig, T. M., Bachmann, M. F., Ochen, S., Hoffmann, U. W., Simard, J. J., Kalberer, C. P., Pircher, H., Ohashi, P. S., Hengartner, H., Zinkernagel, R. M. (1996) On the role of antigen in maintaining cytotoxic T-cell memory. Proc. Natl. Acad. Sci. USA 93, 9716-9723.
287. Balch, C. M., Soong, S. J., Gershenwald, J. E., Thompson, J. F., Reintgen, D. S., Cascinelli, N., Urist, M., McMasters, K. M., Ross, M. I., Kirkwood, J. M., Atkins, M. B., Thompson, J. A., Coit, D. G., Byrd, D., Desmond, R., Zhang, Y., Liu, P. Y., Lyman, G. H., Morabito, A. (2001) Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J. Clin. Oncol. 19, 3622-3634.
288. Altman, J. D., Moss, P. A. H., Goulder, P. J. R., Barouch, D. H., McHeyzer-Williams, M. G., Bell, J. I., McMichael, A. J., Davis, M. M. (1996) Phenotypic analysis of antigen-specific T lymphocytes. Science 274, 94-96.
289. Gustafsson, A., Levitsky, V., Zou, J. Z., Frisan, T., Dalianis, T., Ljungman, P., Ringden, O., Winiarski, J., Ernberg, I., Masucci, M. G. (2000) Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 95, 807-814.
290. Khanna, R., Bell, S., Sherritt, M., Galbraith, A., Burrows, S. R., Rafter, L., Clarke, B., Slaughter, R., Falk, M. C., Douglass, J., Williams, T., Elliott, S. L., Moss, D. J. (1999) Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc. Natl. Acad. Sci. USA 96, 10391-10396.
291. Sensi, M., Salvi, S., Castelli, C., Maccalli, C., Mazzocchi, A., Mortarini, R., Nicolini, G., Herlyn, M., Parmiani, G., Anichini, A. (1993) T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone. J. Exp. Med. 178, 1231-1246.
292. Yee, C., Thompson, J. A., Roche, P., Byrd, D. R., Lee, P. P., Piepkorn, M., Kenyon, K., Davis, M. M., Riddell, S. R., Greenberg, P. D. (2000) Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo. J. Exp. Med. 192, 1637-1644.
293. Sensi, M., Farina, C., Maccalli, C., Lupetti, R., Nicolini, G., Anichini, A., Parmiani, G., Berd, D. (1997) Clonal expansion of T lymphocytes in human melanoma metastases after treatment with a hapten-modified autologous tumor vaccine. J. Clin. Invest. 99, 710-717.
294. Riddell, S. R., Greenberg, P. D. (1997) T cell therapy of human CMV and EBV infection in immunocompromised hosts. Rev. Med. Virol. 7, 181-192.
295. Schmittel, A., Keilholz, U., Thiel, E., Scheibenbogen, C. (2000) Quantification of tumor-specific T lymphocytes with the ELISPOT assay. J. Immunother. 23, 289-295.
296. Kruit, W. H. J., van Baren, N., Humblet, Y., Punt, C. J. A., Avril, M-F., Eseudier, B., Aamdal, S., Eggermont, A. M. M., Hakansson, L., Keilholz, U., et al. (2000) Phase I/II study of vaccination with a MAGE-3 protein plus immunological adjuvant SB AS-2 in HLA class I selected patients with MAGE-3 positive tumors. In American Society of Clinical Oncology, New Orleans, LA.
297. Cebon, J. S., Davis, I. D., Parente, P., Shackleton, M., Hopkins, W., Goldie, H., Maraskovsky, E., Chen, W., Chen, Q., Jackson, H., et al. (2002) A phase I study of NY-ESO-1 ISCOMS in patients with NYESO-1 positive cancers and minimal residual disease. In American Society of Clinical Oncology, Orlando, FL.
298. Yee, C., Savage, P. A., Lee, P. P., Davis, M. M., Greenberg, P. D. (1999) Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J. Immunol. 162, 2227-2234.
299. Clay, T. M., Hobeika, A. C., Mosca, P. J., Lyerly, H. K., Morse, M. A. (2001) Assays for monitoring cellular immune responses to active immunotherapy of cancer. Clin. Cancer Res. 7, 1127-1135.
300. Phan, G. Q., Wang, E., Marincola, F. M. (2001) T-cell-directed cancer vaccines: mechanisms of immune escape and immune tolerance. Expert Opin. Biol. Ther. 1, 511-523.
301. Tan, L. C., Gudgeon, N., Annels, N. E., Hansasuta, P., O'Callaghan, C. A., Rowland-Jones, S., McMichael, A. J., Rickinson, A. B., Callan, M. F. (1999) A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers. J. Immunol. 162, 1827-1835.
302. Romero, P., Cerottini, J. C., Waanders, G. A. (1.998) Novel methods to monitor antigen-specific cytotoxic T-cell responses in cancer immunotherapy. Mol. Med. Today 4, 305-312.
303. Kammula, U. S., Marincola, F. M., Rosenberg, S. A. (2000) Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination. J. Natl. Cancer Inst. 92, 1336-1344.
304. Waanders, G. A., Rimoldi, D., Liénard, D., Carrel, S., Lejeune, F., Dictrich, P. Y., Cerottini, J. C., Romero, P. (1997) Melanoma-reactive human cytotoxic T lymphocytes derived from skin biopsies of delayedtype hypersensitivity reactions induced by injection of an autologous melanoma cell line. Clin. Cancer Res. 3, 685-696.
305. Bendandi, M., Gocke, C. D., Kobrin, C. B., Benko, F. A., Sternas, L. A., Pennington, R., Watson, T. M., Reynolds, C. W., Gause, B. L., Duffey, P. L., Jaffe, E. S., Creekmore, S. P., Longo, D. L., Kwak, L. W. (1999) Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma, Nat. Med. 5, 1171-1177.
306. Fields, S. (2001) PROTEOMICS; proteomics in genomeland. Science 291, 1221-1224,
307. Fields, S., Johnston, M. (2002) GENOMICS: a crisis in postgenomic nomenclature. Science 296, 671-672.
308. Feinstein, A. R., Sosin, D. M., Wells, C. K. (1985) The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N. Engl. J. Med. 312, 1604-1608.
309. Aarnoudse, C. A., van den Doel, P. B., Heemskerk, B., Schrier, P. I. (1999) Interleukin-2-induced, melanoma-specific T cells recognize CAMEL, an unexpected translation product of LAGE-1. Int. J. Cancer 82, 442-448.
310. Wang, R-P., Johnston, L., Zeng, G., Topalian. S. L., Schwartzentruber, D. J., Rosenberg, S. A. (1998) A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. J. Immunol. 161, 3598-3606.
311. Coulie, P. G., Lehmann, F., Lethe, B., Herman, J., Lurquin, C., Andrawiss, M., Boon, T. (1995) A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc. Natl. Acad. Sci. USA 92, 7976-7980.
312. Robbins, P. F., El Gamil, M., Li, Y. F., Fitzgerald, E. B., Kawakami, Y., Rosenberg, S. A. (1997) The intronic region of an incompletely spliced gp100 gene transcript encodes an epitope recognized by melanomareactive tumor-infiltrating lymphocytes. J. Immunol. 159, 303-308.
313. Khong, H. T., Rosenberg, S. A. (2002) Pre-existing immunity to tyrosinase-related protein (TRP)-2, a new TRP-2 isoform, and the NY-ESO-1 melanoma antigen in a patient with a dramatic response to immunotherapy. J. Immunol. 168, 951-956.
314. Eton, O., Legha, S. S., Bedikian, A. Y., Lee, J. J., Buzaid, A. C., Hodges, C., Ring, S. E., Papadopoulos, N. E., Plager, C., East, M. J., Zhan, F., Benjamin, R. S. (2002) Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J. Clin. Oncol. 20, 2045-2052.
315. Khayat, D., Bernard-Marty, C., Meric, J-B., Rixe, O. (2002) Biochemotherapy for advanced melanoma: maybe it is real. J. Clin. Oncol. 20, 2411-2414.
316. Legha, S. S., Ring, S., Eton, O., Bedikian, A., Buzaid, A. C., Plager, C., Papadopoulos, N. (1998) Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J. Clin. Oncol. 16, 1752-1759.
317. Legha, S. S., Ring, S., Eton, O., Bedikian, A., Plager, C., Papadopoulos, N. (1997) Development and results of biochemotherapy in metastatic melanoma: the University of Texas M.D. Anderson Cancer Center experience. Cancer J. Sci. Am. 3 (Suppl. 1), S9-S15.
318. Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., Reyes, F., Lederlin, P., Gisselbrecht, C. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346, 235-242.
319. Zeng, G., Wang, X., Robbins, P. F., Rosenberg, S. A., Wang, R. F. (2001) CD4(+) T cell recognition of MHC class II-restricted epitopes from NYESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production. Proc. Natl. Acad. Sci. USA 98, 3964-3969.
320. Druker, B. J. (2002) STI571 (Gleevec) as a paradigm for cancer therapy. Trends Mol. Med. 8 (Suppl 4), S14-S18.
321. Puccetti, P., Bianchi, R., Fioretti, M. C., Ayroldi, E., Uyttenhove, C., Van Pel, A., Boon, T., Grohmann, U. (1994) Use of a skin test assay to determine tumor-specific CD8+ T cell reactivity. Eur. J. Immunol. 24, 1446-1452.
322. McNeel, D. G., Sehiffman, K., Disis, M. L. (1999) Immunization with recombinant human granulocyte-macrophage colony-stimulating factor as a vaccine adjuvant elicits both a cellular and humoral response to recombinant human granulocyte-macrophage colony-stimulating factor. Blood 93, 2653-2659.
323. Czerkinsky, C., Andersson, G., Ekre, H. P., Nilsson, L. A., Klareskog, L., Ouchterlony, O. (1988) Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon-secreting cells. J. Immunol. Methods 110, 29-36.
324. Maino, V. C., Picker, L. J. (1998) Identification of functional subsets by flow cytometry: intracellular detection of cytokine expression. Cytometry 34, 207-215.
325. Scheffold, A., Assenmacher, M., Reiners-Schramm, L., Lauster, R., Radbruch, A. (2000) High-sensitivity immunofluorescence for detection of the pro- and anti-inflammatory cytokines gamma interferon and interleukin-10 on the surface of cytokine-secreting cells. Nat. Med. 6, 107-110.